The first Phase 3 results for Eli Lilly’s daily pill orforglipron show statistically significant reductions in blood sugar and body weight in patients with type 2 diabetes. The pharmaceutical giant plans global regulatory submissions starting at the end of this year. The post Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop…
Walgreens has completed its sale to private equity firm Sycamore Partners, raising concerns that the deal could lead to widespread store closures, layoffs and reduced access to healthcare in vulnerable communities. The post What’s Next for Walgreens Following its Private Equity Sale? appeared first on MedCity News.
I asked if I could purchase the brace myself and bring it to the surgery. The answer was an unequivocal no: the health insurer’s contracted rate required me to purchase the brace from the hospital as part of the procedure. The post A 2,100% Markup: My Battle with a Vastly Overpriced Knee Brace — and…
That is the title of an interesting panel from USC Schaeffer Center on Coverage with Evidence Development (CED). It includes an interview with Tamara Syrek Jensen, Director, of the Coverage & Analysis Group within the Centers for Medicare & Medicaid Services. After the interview, there is a panel discussion with Darius Lakdawalla of USC, Peter…
[Sponsored] In an interview, Abarca President and COO Adriana Ramirez shared why the future of healthcare must prioritize the human experience, powered by technology. The post Pharmacy as the Front Line of the Consumer Experience Revolution appeared first on MedCity News.
Providence researchers discuss their recently published results on the impact of ambient clinical intelligence on documentation workload
By KIM BELLARD News flash: America is not a very happy place these days. No, I’m not talking about the current political divide (which is probably more accurately described as a chasm), at least not directly. I’m referring to the latest results from the World Happiness Report, which found that the U.S. has slid to…
Lantern has publicly released its methodology for calculating surgical savings, and is inviting others to do the same. The post Lantern Unveils Savings Methodology to Increase Transparency for Specialty Care Pricing appeared first on MedCity News.
Oral diseases cost Americans almost $140 billion annually. What will it take to bring these costs down? The post If We Treated Tooth Decay Like We Treat Heart Disease, We’d Save Billions appeared first on MedCity News.
According to a Health Affairs Scholar paper by Geoffrey Joyce out this month, the answer is ‘yes’. He writes: Most PBM contracts tie their compensation to a percentage of a drug’s list price, creating a financial incentive to favor high-cost, high-rebate drugs on plan formularies at the expense of lower-cost generics and biosimilars. Furthermore, the…